Hématologie
The cytostatic drug bortezomib is a reversible proteasome inhibitor. The proteasomes inhibited by bortezomib are multienzyme complexes that occur in all cells (and increasingly in cancer cells) and degrade proteins.
Bortezomib (as a mannitol boronic ester)
Bortezomib is a proteasome inhibitor. It is specifically designed to inhibit the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitin-bound proteins. The ubiquitin degradation pathway plays an important role in regulating the metabolism of certain proteins, and thus in maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents the targeted proteolysis and causes a variety of signaling cascades within the cell that ultimately lead to the death of the cancer cell.
Monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for hematopoietic stem cell transplantation.
In combination with melphalan and prednisone indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with hematopoietic stem cell transplantation.
In combination with dexamethasone, or with dexamethasone and thalidomide, indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with hematopoietic stem cell transplantation.
In combination with rituximab, cyclophosphamide, doxorubicin and prednisone indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for hematopoietic stem cell transplantation.
Powder for solution for injection:
Not all pack sizes may be marketed.
